News

/
/
/
PTJA09 – ‘Brolucizumab for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD)’ project plan now available

PTJA09 – ‘Brolucizumab for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD)’ project plan now available

The final project plan  of the relative effectiveness of  ‘Brolucizumab for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD)’ is now available for access.

The final assessment report will be published on 12th March, 2020.

Below is the documentation provided by the Joint Assessment authoring team.

PTJA09 Final Project Plan

This website uses cookies to ensure you get the best experience on our website. By using the website you agree to our Privacy Policy and our Terms of Use.